Recent

% | $
Quotes you view appear here for quick access.

Biodel Inc. (BIOD) Message Board

  • stvwingert stvwingert Sep 27, 2011 10:43 PM Flag

    If this were an IPO

    What would people pay..for $1 per share in cash and very promising, but preclinical, analog candidates..and Linjeta hanging out there with a chance if 2 more phase 3 trails are ever completed.

    Are those promising fast-acting, fast absorbing etc. candidates worth negative 27 cents per share? (given that we're 27 cents below cash?)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I bought more today and will continue to do so until I hear if/when they are taking analogs to the clinic. I think Humalog goes off patent first out of the big 3. I'm bettting Lily will want to give it a try in the clinic to protect their patent imho.

      • 2 Replies to isaa0113
      • isaa,

        you will absolutely hear in November that they are taking an analog version into the clinic. It will either be with Lilly or Sanofi as a partner or by using API from a foreign source. Either way, Biodel is taking an analog version into the clinic fairly soon. I agree with you that it is most likely Lilly...but for slightly different reasons.

 
BIOD
0.2613-0.0528(-16.81%)Jun 24 4:00 PMEDT